Start here if you're new
what it is
ZIVO tries to turn algae-based compounds into animal and human health products, but right now you are mostly buying the attempt.
how it gets paid
Last year Zivo Bioscience made $157K in revenue. poultry health applications was the main engine at $63K, or 40% of sales.
what just happened
Latest quarter revenue reached $119K, but EPS fell to -$1.82, so the business grew off a tiny base while losses stayed brutal.
At a glance
C++ balance sheet — some cracks in the foundation
25/100 earnings predictability — expect surprises
-$4.23 fy2024 eps est
$0M fy2024 rev est
n/a operating margin
xvary composite: 31/100 — weak
What they do
ZIVO tries to turn algae-based compounds into animal and human health products, but right now you are mostly buying the attempt.
Its moat is IP (intellectual property → patents, strains, and production know-how → legal fences around the recipe). With just 7 employees, ZIVO has to make its ideas work harder than its payroll. If its poultry and animal-health studies hold up, you are not buying algae powder, you are buying a protected formula competitors cannot legally copy fast.
How they make money
$157K
annual revenue
poultry health applications
$63K
bovine mastitis applications
$31K
human immune modification
$24K
algal biomass for human consumption
$22K
skin health and anti-aging biomass
$17K
The products that matter
research and licensing platform
Algae-based Bioactive Ingredients
$209K trailing revenue · +164.5% from a year ago
this is the commercial base today. $209K in trailing revenue sounds better after 164.5% growth, but it is still only $209K.
current revenue base
animal health r&d
Coccidiosis Treatment for Broiler Chickens
42-day study
the poultry program is still an experiment, not a business. The 42-day study matters because this company needs product proof before it can earn commercial trust.
pipeline bet
future human health optionality
Human Health Ingredient Opportunity
pre-commercial
management talks about human health potential, but the numbers on this page still read like an R&D operation: $209K in trailing revenue and an $8.49M net loss.
option value
Key numbers
n/a
operating margin
Prior margin KPI failed sanity check — verify in filings. Operating margin means profit after running the business. Plain English: ZIVO spent vastly more than it brought in, so this is still a science project financially.
$157K
annual revenue
That is the hard SEC-filed revenue number. Plain English: the commercial business is tiny next to a roughly $35M valuation.
$4.23
FY2024 EPS
EPS means profit per share. Plain English: each share took a $4.23 loss in FY2024, so you are paying for future proof, not current earnings.
$0M
long-term debt
Long-term debt means money owed beyond a year. Plain English: ZIVO has no material debt load, which removes one common biotech failure mode.
Financial health
C++
strength
- balance sheet grade C++ — below average — limited financial resources
- risk rank 5 — safer than 5% of stocks
- price stability 5 / 100
- long-term debt $0M (1% of capital)
C++ — below average. watch for debt servicing and cash burn.
Total return vs. market
Return history isn't available for ZIVO right now.
source: institutional data · return history unavailable
What just happened
missed estimates
Latest quarter revenue reached $119K, but EPS fell to -$1.82, so the business grew off a tiny base while losses stayed brutal.
Revenue rose 81% vs. prior year to $119K, and gross margin was 32.9%. That is the contrast: some sales traction exists, but the income statement is still dominated by losses.
$119K
revenue
$1.82
eps
32.9%
gross margin
the number that mattered
$119K matters because an 81% growth rate sounds exciting until you remember the entire quarter still did less revenue than many restaurants.
source: SEC filing, latest reported quarter
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
The #1 risk is commercialization failure of the algae platform. ZIVO has $209K in trailing revenue and an $8.49M net loss, so almost the entire thesis depends on turning research into actual customer demand.
med
Commercial scale still does not exist
The company generated $209K in trailing revenue while losing $8.49M. That is not a rough quarter. That is a business model still under construction.
If sales do not move beyond the current hundreds-of-thousands range, the market eventually stops paying for possibility.
med
Funding risk is embedded in the math
ZIVO has $0M in long-term debt, which sounds clean. But a C++ balance sheet and an $8.49M net loss mean future capital needs can still show up through dilution or other financing.
No debt reduces insolvency pressure. It does not remove financing pressure.
med
Key-person turnover hit the finance seat
The Dec 2025 CFO departure adds execution risk at the exact moment the company needs discipline around cash, milestones, and outside credibility.
At this size, management changes are not background noise. They can slow everything.
med
The pipeline is still binary
The coccidiosis program and broader algae platform are promising only if studies convert into products people buy. The 42-day study is progress. It is not proof.
When one platform carries the story, a setback can hit both sentiment and valuation at once.
This risk stack is easy to summarize: $209K in trailing revenue is supporting a $35M equity value while the company loses $8.49M. That leaves very little room for delays.
source: institutional data · regulatory filings · risk analysis
Pay attention to
the number that matters
Revenue has to stop looking microscopic
Trailing revenue is $209K and reported annual revenue is $157K. Until one of those figures steps up meaningfully, the thesis is still mostly narrative.
calendar
Next earnings report
Expected on or around March 20, 2026. You want to see whether losses narrow, revenue scales, or management is still telling the same story with different slides.
execution risk
Permanent CFO hire
The company named an interim CFO in Dec 2025. A permanent appointment would not fix the business, but it would remove one obvious source of friction.
pipeline trend
From study results to customer adoption
The 42-day poultry study is a checkpoint, not the finish line. Watch for any sign that trials convert into repeatable commercial demand.
Analyst rankings
earnings predictability
25 / 100
A 25 / 100 predictability score means the financials are hard to model. In human-speak, analysts should expect surprises because the business is still too small and too early.
beta
0.8
Beta measures how much a stock tends to move with the market. At 0.8, ZIVO is less tied to the index and more tied to its own headlines.
source: institutional data
Institutional activity
institutional ownership data for ZIVO is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$10
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive